Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for ATR-04 in EGFRi-Associated Rash. The expected timing is based on the latest available company guidance and may change.
8/22/24- Received IND clearance. 9/18/24- Receives Fast Track Designation. 9/24/24 Presentation at EADV 2024. 4/25/25- Trial presentation at ASCO'25. 8/27/25- First patient dosed. 11/12/25:- Company reiterates first patient dosed in Ph1/2 ATR-04 trial in August 2025. 02/24/26:- MD Anderson added as sixth site for Ph1/2 ATR-04 trial NCT06830863; Cohort 1 enrolling eight patients. 02/27/26:- Company expects topline data from first ATR-04 Ph1/2 cohort around Mid-2026. 05/13/26:- MD Anderson site reiterated. Topline Ph1/2 Cohort 1 data expected H2 2026. 08/12/26:- Cohort 1 enrollment continues at six sites. Topline Ph1/2 data is expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.